RFL - Rafael Pharmaceuticals' lead compound CPI-613 on go with early-stage study for pancreatic cancer

Rafael Pharmaceuticals' ([[RFL]] +4.5%) partner Ono Pharmaceutical has commenced, a Phase 1 study of Rafael’s lead compound, CPI-613 in Japan for patients with pancreatic cancer.The study will evaluate the efficacy and safety of Rafael’s lead compound, CPI-613 ((devimistat)), labeled as ONO-7912 in Japan, in combination with modified FOLFIRINOX ((mFFX)) in patients with pancreatic cancer refractory or intolerance to chemotherapy including gemcitabine.CPI-613 (devimistat) is used for the treatment of older patients (at least 60 years of age) with relapsed/refractory acute myeloid leukemia.In June 2019, the Company announced an out-licensing agreement with Japan-based Ono Pharmaceutical to develop and commercialize devimistat.Ono will work with Rafael in supporting the trial through lending its deep expertise in the region.

For further details see:

Rafael Pharmaceuticals’ lead compound CPI-613 on go with early-stage study for pancreatic cancer